Exclusive

Publication

Byline

Location

Clinical Trial: A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07808788) titled 'A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through... Read More


Clinical Trial: The Feasibility of Electrical Impedance Tomography to Guide Non-invasive Respiratory Interventions in Chronic Respiratory Disease

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07810283) titled 'The Feasibility of Electrical Impedance Tomography to Guide Non-invasive Respiratory Inter... Read More


Clinical Trial: Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07810569) titled 'Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients' on Sept.... Read More


Clinical Trial: Cl-Pharm-IBS-ML-2026

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809646) titled 'Cl-Pharm-IBS-ML-2026' on Sept. 03. Brief Summary: The purpose of this study is to identif... Read More


Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, Sept. 10 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More


Clinical Trial: Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809724) titled 'Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder' on Jan. 23... Read More


Singapore Clinical Trial: An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY 3771249 as monotherapy or combination with other cancer treatments in participants with solid tumors harboring a KRAS G12D mutation

Singapore, Sept. 10 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and... Read More


Clinical Trial: Artificial Intelligence - Based Opportunistic Coronary Artery Calcium Scoring on Routine Chest-CT Scan

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07808593) titled 'Artificial Intelligence - Based Opportunistic Coronary Artery Calcium Scoring on Routine C... Read More


Singapore Clinical Trial: A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.

Singapore, Sept. 10 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asci... Read More


Singapore Clinical Trial: A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by asciminib plus blinatumomab in pediatric, adolescent, and young adult participants with relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

Singapore, Sept. 10 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib wit... Read More